Huons Global Co., Ltd.

A084110

KR7084110006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 13/05/2024 BST			5-day change	1st Jan Change
21,950 ^KRW	+1.62%		0.00%	-7.19%

03-20	Huons Global Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Huons Global Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Tranche Update on Huons Global Co., Ltd.'s Equity Buyback Plan announced on March 16, 2022.

September 16, 2022 at 08:05 am

From April 1, 2022 to June 30, 2022, the company has repurchased 76,728 shares, representing 0.62% for KRW 2,403.18 million. With this, the company has completed the repurchase of 162,128 shares, representing 1.31% for KRW 4,993.95 million under the buyback announced on March 16, 2022.

Latest news about Huons Global Co., Ltd.

Huons Global Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Huons Global Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Huons Global Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Huons Global Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Huons Global Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Tranche Update on Huons Global Co., Ltd.'s Equity Buyback Plan announced on March 16, 2022.	16/09/22	CI
Tranche Update on Huons Global Co., Ltd.'s Equity Buyback Plan announced on March 16, 2022.	16/09/22	CI
Huons Global Co., Ltd.'s Equity Buyback announced on March 16, 2022, has expired with 162,128 shares, representing 1.31% for KRW 4,993.95 million.	15/09/22	CI
Huons Global Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
HuM&C Co., Ltd. acquired 75.32% of stake in Hubena Co., Ltd. from HunoLab and Huons Global Co., Ltd. for KRW 28,501.2.	14/07/22	CI
Tranche Update on Huons Global Co., Ltd.'s Equity Buyback Plan announced on March 16, 2022.	17/06/22	CI
Huons Global Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
Huons Global Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	23/03/22	CI
Huons Global Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.	16/03/22	CI
Huons Global Co., Ltd. authorizes a Buyback Plan.	15/03/22	CI
Huons Global Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
Huons Global Co., Ltd. announced that it has received KRW 50 billion in funding	31/10/21	CI
Huons Global Co., Ltd. announced that it expects to receive KRW 50 billion in funding	27/10/21	CI
Huons Global : South Korean consortium to produce Russia's Sputnik Light vaccine	28/06/21	RE
Imeik Technology Development Co.,Ltd. signed a contract to acquire a 10.5% stake of Huons Bio Pharma Co.,Ltd. from Huons Global Co., Ltd. for KRW 53.5 billion.	23/06/21	CI
Huons Global : S.Korean consortium to produce 100 mln doses a month of Russia's Sputnik V vaccine	16/04/21	RE
Tranche Update on Huons Global Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.	23/02/21	CI
Tranche Update on Huons Global Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.	23/02/21	CI
Huons Global Co., Ltd.'s Equity Buyback announced on August 14, 2020, has expired with 133,523 shares, representing 1.12% for KRW 3,990.62 million.	17/02/21	CI
Tranche Update on Huons Global Co., Ltd.'s Equity Buyback Plan announced on August 14, 2020.	23/11/20	CI

Chart Huons Global Co., Ltd.

Duration

Period

More charts

Company Profile

Huons Global Co., Ltd., formerly, Huons Co., Ltd. is Kore-based entity principally engaged in the manufacture and distribution of pharmaceutical products. Along with its subsidiaries, the Company operates its business through two segments: pharmaceutical segment and glass container segment. The pharmaceutical segment produces pharmaceutical products including parenteral injections such as lidocaines, merit C injections; tablets such as phentermines, diet pills and others; capsules such as Daisen and Fuxetine and other ethical and over-the-counter drugs. The glass container segment produces ampoules, vials, cartridges and caps for used of medicals, foods and cosmetics. The Company also manufactures medical devices such as kits, derma injectors and other injector.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
HUONS GLOBAL CO., LTD.	-7.19%	199M
MERCK KGAA	+15.09%	78.37B
KYOWA KIRIN CO. LTD.	+11.65%	9.08B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+54.35%	4.85B
SK BIOPHARMACEUTICALS CO., LTD.	-12.85%	5.06B
YUHAN CORPORATION	+1.60%	3.85B
BETTA PHARMACEUTICALS CO., LTD.	-20.85%	2.36B
INDIVIOR PLC	+16.88%	2.37B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.25%	2.22B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+24.62%	2.27B